Accordingly, cotreatment with anti-PD-1 and anti-UCA1 retarded tumor growth and increased the survival of xenografted mice, demonstrating synergistic efficacy in bladder cancer [93]. Here, PDCD1 is linked to urinary bladder carcinoma.